Parkinson's Disease (PD) Clinical Trial
Official title:
ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group
study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an
investigational formulation of amantadine, dosed once nightly at bedtime for the treatment of
levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). The novel
pharmacokinetic profile of ADS-5102 is expected to achieve i) maximal concentrations in the
early morning through mid-day, when LID can be troublesome, and ii) lower concentrations in
the evening, potentially reducing the negative impact of amantadine on sleep. This
pharmacokinetic profile could enable higher doses to be tolerated with a once-nightly ER
formulation than can be tolerated with an immediate-release formulation. The once-nightly
dosing regimen may also provide enhanced convenience and compliance.
In a previous clinical study, ADS-5102 met its primary endpoint; LID was significantly
reduced as measured by the change in UDysRS score over 8 weeks vs. placebo.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02170376 -
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT02169479 -
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
|
Phase 1 | |
| Completed |
NCT02169895 -
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide
|
Phase 1 | |
| Completed |
NCT02778594 -
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
|
Phase 1 | |
| Completed |
NCT02169453 -
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
|
Phase 1 | |
| Completed |
NCT04380142 -
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
|
Phase 3 | |
| Withdrawn |
NCT06118294 -
Efficacy of Probiotics for Parkinson Disease (PD)
|
N/A | |
| Recruiting |
NCT05916157 -
An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
|
||
| Completed |
NCT03033498 -
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
|
Phase 1 | |
| Completed |
NCT02169427 -
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
|
Phase 1 | |
| Completed |
NCT02834507 -
Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04379050 -
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
|
Phase 3 | |
| Completed |
NCT02169440 -
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
|
Phase 1 | |
| Completed |
NCT02202551 -
Open-Label Safety Study of ADS-5102 in PD Patients With LID
|
Phase 3 | |
| Completed |
NCT01398748 -
Intranasal Glutathione in Parkinson's Disease
|
Phase 1 | |
| Recruiting |
NCT06107426 -
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
|
||
| Completed |
NCT02169466 -
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
|
Phase 1 | |
| Recruiting |
NCT03732898 -
Coordinated Reset Deep Brain Stimulation
|
N/A | |
| Completed |
NCT02799381 -
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
|
Phase 3 | |
| Terminated |
NCT03829657 -
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
|
Phase 3 |